Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus substantially reduced RSV lower respiratory tract.
Study demonstrated a 90% effectiveness of nirsevimab in preventing RSV-associated hospitalizations in infants, with a significant finding being the timely vaccination's role in offering protection.
Maternal influenza vaccination was associated with reduced risk for influenza-associated hospitalizations and ED visits among infants younger than 6 months.
Percentage of Mycoplasma pneumoniae infections up since September 2023, research shows medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.